Trial Profile
Prospective, Single-Arm, Multi-Centre, Observational Registry to Further Validate Safety and Efficacy of the Nobori DES in Real-World Patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Oct 2019
Price :
$35
*
At a glance
- Drugs Umirolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms e-NOBORI
- Sponsors Terumo
- 06 Oct 2019 Status changed from active, no longer recruiting to completed.
- 03 Jul 2016 Planned End Date changed from 1 Apr 2016 to 1 Apr 2017.
- 03 Jul 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016.